What is the 13F Pro Quality Score for LUNG?

13F Pro ranks Pulmonx Corp (LUNG) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LUNG's current score at https://13fpro.ai/research/LUNG (free sign-up required for the full ranking).

Where does 13F Pro source LUNG data?

All Pulmonx Corp fundamentals and ownership data come directly from SEC EDGAR. Pulmonx Corp files with the SEC under CIK 1127537. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LUNG in?

Pulmonx Corp (LUNG) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LUNG research updated on 13F Pro?

LUNG's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Pulmonx Corp(LUNG)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1127537 LUNG stock profile & AI dashboard →

13F Pro Quality Score

23.9/100

Rank #2,600 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

73.0/100

Profitability

9.8/100

Balance Sheet

4.0/100

Earnings Quality

30.0/100

Free Cash Flow

10.3/100

Institutional Flow

17.1/100

Revenue Scale

16.1/100

Dilution Risk

8.0/100

LUNG Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Pulmonx Corp (LUNG), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LUNG at 23.9/100 on a 32-signal composite quality model, placing it at rank #2,600 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (4.0) and profitability (9.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Pulmonx Corp reports quarterly revenue of $20.6M, net income of $-13.7M, an operating margin of -62.9%. Top institutional holders of LUNG by reported 13-F value include PRIMECAP MANAGEMENT CO/CA/, MORGAN STANLEY, Soleus Capital Management, L.P., based on the most recent SEC filings. LUNG trades on the Nasdaq exchange and files with the SEC under CIK 1127537. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LUNG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Pulmonx Corp directly from SEC EDGAR. Pulmonx Corp's 13F Pro composite quality score has ranged between 8 and 56 since 2021, currently 23.9 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

Revenue

Q1 2026

$20.6M

Net Income

Q1 2026

$-13.7M

Free Cash Flow

Q1 2026

$-10.1M

Operating Margin

Q1 2026

-62.9%

D/E Ratio

Q1 2026

0.82

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+8.0% YoY

$90.5MFY 2025

FY22 $53.7MFY23 $68.7MFY24 $83.8MFY25 $90.5M

Net Income

+4.2% YoY

$-54.0MFY 2025

FY22 $-58.9MFY23 $-60.8MFY24 $-56.4MFY25 $-54.0M

Operating Income

+7.0% YoY

$-53.7MFY 2025

FY22 $-58.6MFY23 $-61.9MFY24 $-57.7MFY25 $-53.7M

EPS (Diluted)

+7.6% YoY

$-1.33FY 2025

FY22 $-1.59FY23 $-1.60FY24 $-1.44FY25 $-1.33

Total Assets

-20.6% YoY

$129.3MFY 2025

FY22 $193.7MFY23 $177.8MFY24 $162.8MFY25 $129.3M

Total Debt

-7.8% YoY

$37.2MFY 2025

FY22 $17.4MFY23 $39.4MFY24 $40.4MFY25 $37.2M

Op. Cash Flow

-2.7% YoY

$-32.4MFY 2025

FY22 $-45.1MFY23 $-37.6MFY24 $-31.5MFY25 $-32.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$90.5M +8.0%	$83.8M +22.0%	$68.7M +28.0%	$53.7M +10.8%	$48.4M +47.9%	$32.7M
Net Income	$-54.0M +4.2%	$-56.4M +7.3%	$-60.8M -3.3%	$-58.9M -21.1%	$-48.7M -51.0%	$-32.2M
Operating Income	$-53.7M +7.0%	$-57.7M +6.8%	$-61.9M -5.6%	$-58.6M -24.0%	$-47.3M -46.3%	$-32.3M
EPS (Diluted)	$-1.33 +7.6%	$-1.44 +10.0%	$-1.60 -0.6%	$-1.59 -17.8%	$-1.35 +57.3%	$-3.16
Total Assets	$129.3M -20.6%	$162.8M -8.4%	$177.8M -8.2%	$193.7M -17.6%	$235.2M -10.8%	$263.7M
Total Debt	$37.2M -7.8%	$40.4M +2.4%	$39.4M +126.2%	$17.4M -0.5%	$17.5M +0.8%	$17.4M
Operating Cash Flow	$-32.4M -2.7%	$-31.5M +16.1%	$-37.6M +16.6%	$-45.1M -8.9%	$-41.4M -35.1%	$-30.6M

AI Insight: LUNG Ratio Trends

Operating margin improved 12.7pp from Q4 2024 to Q4 2025 but deteriorated sharply to -62.9% in Q1 2026.

• Operating margin improved from -56.5% in Q4 2024 to -43.8% in Q4 2025 before reversing to -62.9% in Q1 2026.

• Debt-to-equity ratio more than doubled from 0.37 in Q2 2024 to 0.82 in Q1 2026.

• ROE deteriorated from -60.6% in Q2 2024 to -119.3% in Q1 2026, hitting the worst level in the dataset.

⚠ Q4 2025 showed meaningful margin improvement which completely reversed in Q1 2026, suggesting operational volatility.

⚠ Rising leverage trend with D/E increasing consistently since Q2 2024 amid persistent losses.

Get alerted when LUNG's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Pulmonx Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LUNG

PRIMECAP MANAGEMENT CO/CA/
$6.1M4,724,991 sh
MORGAN STANLEY
$5.2M3,993,562 sh
Soleus Capital Management, L.P.
$3.6M2,788,323 sh
BlackRock, Inc.
$3.4M2,661,607 sh
ExodusPoint Capital Management, LP
$2.5M1,943,834 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.1M1,634,264 sh
BANK OF AMERICA CORP /DE/
$1.5M1,166,826 sh
DEUTSCHE BANK AG\
$1.5M1,163,678 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.2M944,492 sh
STATE STREET CORP
$1.0M809,116 sh

Fund	Value	Shares
PRIMECAP MANAGEMENT CO/CA/	$6.1M	4,724,991
MORGAN STANLEY	$5.2M	3,993,562
Soleus Capital Management, L.P.	$3.6M	2,788,323
BlackRock, Inc.	$3.4M	2,661,607
ExodusPoint Capital Management, LP	$2.5M	1,943,834
VANGUARD CAPITAL MANAGEMENT LLC	$2.1M	1,634,264
BANK OF AMERICA CORP /DE/	$1.5M	1,166,826
DEUTSCHE BANK AG\	$1.5M	1,163,678
GEODE CAPITAL MANAGEMENT, LLC	$1.2M	944,492
STATE STREET CORP	$1.0M	809,116

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LUNG on your watchlist

Track score changes the day Pulmonx Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LUNG a good stock to buy?

13F Pro's AI-powered analysis of Pulmonx Corp (LUNG) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LUNG are available on the LUNG stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own LUNG?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LUNG. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Pulmonx Corp's investment landscape.